MST CONTINUS 200 Milligram Granules Prolonged Release
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
05-06-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
MORPHINE SULFATE
Available from:
Napp Pharmaceuticals Limited
INN (International Name):
MORPHINE SULFATE
Dosage:
200 Milligram
Pharmaceutical form:
Granules Prolonged Release
Prescription type:
Product subject to prescription which may not be renewed (A)
Authorization status:
Withdrawn
Authorization date:
0000-00-00
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
MST CONTINUS suspension 200 mg.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Morphine equivalent to Morphine Sulphate 200 mg
For full list of excipients see 6.1
3 PHARMACEUTICAL FORM
Pink granules
Prolonged release granules for oral suspension.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the prolonged relief of severe and intractable pain.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration: oral
The contents of one sachet should be mixed with at least 30 ml water or sprinkled on to soft food, for example yogurt.
The controlled release granules must be suspended whole and ingested immediately, but not be broken, chewed or
crushed. The administration of broken, chewed or crushed morphine granules leads to a rapid release and absorption of
a potentially fatal dose of morphine _(see section 4.9, Overdose)._
MST CONTINUS suspension should be used at 12-hourly intervals. The dosage is dependent upon the severity of the
pain, the patient's age and previous history of analgesic requirements.
Adults:
A patient presenting with severe pain, uncontrolled by weaker opioids (e.g. dihydrocodeine) should normally be started
on 30 mg 12 hourly. Patients previously on normal release oral morphine should be given the same total daily dose as
MST CONTINUS suspension but in divided doses at 12-hourly intervals.
Increasing severity of pain will require an increased dosage of the suspension. Higher doses should be made, where
possible in 30-50% increments as required. The correct dosage for any individual patient is that which is sufficient to
control pain with no, or tolerable, side effects for a full 12 hours. It is recommended that the 200 mg strength is
reserved for patients who have already bee
Read the complete document
